SEC Company Response from aTYR PHARMA INC (ATYR) (CIK 0001339970) (ATYR) — Feb 3, 2020
aTYR PHARMA INC (ATYR) (CIK 0001339970)
Date: Feb. 3, 2020 · CIK: 0001339970 · Accession: 0001564590-20-002996
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235951
Letter
life-corresp.htm
OPPENHEIMER & CO. INC.
85 Broad Street
New York, New York 10004
February 3, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
aTyr Pharma, Inc.
Registration Statement on Form S-1, as amended File
No. 333-235951
Ladies and Gentlemen:
In accordance with the above-referenced Registration Statement, and pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as the representative of the several underwriters (the “Representative”), hereby joins in the request of aTyr Pharma, Inc. that the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on Tuesday, February 4, 2020, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned, as the representative of the several underwriters, represents that the several underwriters have and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
OPPENHEIMER & CO. INC
Show Raw Text
CORRESP 1 filename1.htm life-corresp.htm OPPENHEIMER & CO. INC. 85 Broad Street New York, New York 10004 February 3, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: aTyr Pharma, Inc. Registration Statement on Form S-1, as amended File No. 333-235951 Ladies and Gentlemen: In accordance with the above-referenced Registration Statement, and pursuant to Rule 461 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned, as the representative of the several underwriters (the “Representative”), hereby joins in the request of aTyr Pharma, Inc. that the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on Tuesday, February 4, 2020, or as soon thereafter as practicable. Pursuant to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned, as the representative of the several underwriters, represents that the several underwriters have and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, OPPENHEIMER & CO. INC As representative of the Several Underwriters OPPENHEIMER & CO. INC. By: /s/ Peter Bennett Name: Peter Bennett Title: Managing Director